Argentarii LLC Sells 784 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Argentarii LLC reduced its stake in Thermo Fisher Scientific by 43.4%, selling 784 shares and ending up with a total of 1,024 shares valued at approximately $415,000.
• Insider trading activity saw EVP Gianluca Pettiti selling 400 shares on July 25, and CAO Joseph R. Holmes selling 385 shares on August 29, with both executives experiencing a significant decrease in their ownership percentages.
• Thermo Fisher Scientific reported a 2.9% increase in quarterly revenue year-over-year, generating $10.86 billion for the quarter and exceeding analyst expectations for earnings per share.

Argentarii LLC cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 43.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,024 shares of the medical research company's stock after selling 784 shares during the period. Argentarii LLC's holdings in Thermo Fisher Scientific were worth $415,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Revolve Wealth Partners LLC grew its holdings in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after buying an additional 20 shares in the last quarter. Intergy Private Wealth LLC grew its stake in shares of Thermo Fisher Scientific by 5.8% in the 1st quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company's stock worth $208,000 after acquiring an additional 23 shares in the last quarter. Root Financial Partners LLC lifted its position in shares of Thermo Fisher Scientific by 5.0% during the first quarter. Root Financial Partners LLC now owns 506 shares of the medical research company's stock valued at $252,000 after purchasing an additional 24 shares in the last quarter. Rossmore Private Capital boosted its holdings in Thermo Fisher Scientific by 0.5% during the first quarter. Rossmore Private Capital now owns 4,652 shares of the medical research company's stock worth $2,315,000 after purchasing an additional 24 shares during the last quarter. Finally, ARS Wealth Advisors Group LLC increased its stake in Thermo Fisher Scientific by 1.6% in the 1st quarter. ARS Wealth Advisors Group LLC now owns 1,563 shares of the medical research company's stock valued at $778,000 after buying an additional 25 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Activity

In other news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Trading Down 1.1%

Shares of TMO stock opened at $474.54 on Tuesday. The company has a market capitalization of $179.19 billion, a PE ratio of 27.45, a price-to-earnings-growth ratio of 2.56 and a beta of 0.75. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $623.77. The business's fifty day moving average is $472.99 and its 200 day moving average is $448.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company's quarterly revenue was up 2.9% compared to the same quarter last year. During the same period in the prior year, the company earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's payout ratio is currently 9.95%.

Analysts Set New Price Targets

TMO has been the subject of several recent analyst reports. Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the company an "outperform" rating in a report on Tuesday, September 2nd. Scotiabank upgraded Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective for the company in a research note on Friday, July 11th. Evercore ISI cut their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. HSBC reaffirmed a "hold" rating and issued a $510.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, Hsbc Global Res downgraded shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $588.35.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.